<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>No clinically validated biomarkers exist to image <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> responses to antiangiogenic therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we report the utility of hyperpolarized (13)C magnetic resonance spectroscopy (MRS) to detect the early effects of anti-VEGF therapy </plain></SENT>
<SENT sid="2" pm="."><plain>In two <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e>, displaying differential sensitivity to VEGF blockade, we compared hyperpolarized MRS with measurements of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> perfusion using dynamic contrast agent-enhanced (DCE)-MRI and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cellularity using diffusion-weighted MRI of the apparent diffusion coefficient (<z:chebi fb="49" ids="35181">ADC</z:chebi>) of tissue water </plain></SENT>
<SENT sid="3" pm="."><plain>In <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> sensitive to anti-VEGF therapy, (13)C flux between hyperpolarized [1-(13)C]<z:chebi fb="1" ids="15361">pyruvate</z:chebi> and [1-(13)C]<z:chebi fb="4" ids="24996">lactate</z:chebi> decreased after anti-VEGF therapy and correlated with reduced perfusion </plain></SENT>
<SENT sid="4" pm="."><plain>Production of [1,4-(13)C(2)]malate from hyperpolarized [1,4-(13)C(2)]fumarate increased in parallel with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell <z:mp ids='MP_0001651'>necrosis</z:mp>, preceding any change in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:chebi fb="49" ids="35181">ADC</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> that were less sensitive to anti-VEGF therapy showed an increase in (13)C flux from hyperpolarized [1-(13)C]<z:chebi fb="1" ids="15361">pyruvate</z:chebi> and an increase in uptake of a <z:chebi fb="0" ids="33375">gadolinium</z:chebi> contrast agent, whereas <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:chebi fb="49" ids="35181">ADC</z:chebi> decreased </plain></SENT>
<SENT sid="6" pm="."><plain>Increased label flux could be explained by vascular normalization after VEGF blockade, increasing delivery of hyperpolarized [1-(13)C]<z:chebi fb="1" ids="15361">pyruvate</z:chebi> as observed </plain></SENT>
<SENT sid="7" pm="."><plain>Despite the minimal response of these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> to treatment, with only a minor increase in <z:mp ids='MP_0001651'>necrosis</z:mp> observed histologically, production of [1,4-(13)C(2)]malate from hyperpolarized [1,4-(13)C(2)]fumarate in therapy-resistant <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> also increased </plain></SENT>
<SENT sid="8" pm="."><plain>Together, our findings show that hyperpolarized (13)C MRS detects early responses to anti-VEGF therapy, including vascular normalization or vascular destruction and cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
</text></document>